Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: April 28, 2022
Cancer
is
one
of
the
major
diseases
threatening
human
life
and
health
worldwide.
Epigenetic
modification
refers
to
heritable
changes
in
genetic
material
without
any
nucleic
acid
sequence
results
phenotypic
changes.
modifications
regulate
many
biological
processes,
such
as
growth,
aging,
various
diseases,
including
cancer.
With
advancement
next-generation
sequencing
technology,
role
RNA
cancer
progression
has
become
increasingly
prominent
a
hot
spot
scientific
research.
This
review
studied
several
common
modifications,
N6-methyladenosine,
5-methylcytosine,
pseudouridine.
The
deposition
roles
these
coding
noncoding
RNAs
are
summarized
detail.
Based
on
background,
this
expression,
function,
underlying
molecular
mechanism
their
regulators
further
discussed
some
existing
small-molecule
inhibitors.
More
in-depth
studies
needed
broaden
understanding
epigenetics
diagnosis,
treatment,
prognosis.
Journal of Hematology & Oncology,
Journal Year:
2021,
Volume and Issue:
14(1)
Published: Aug. 9, 2021
Abstract
MYC
oncogene
is
a
transcription
factor
with
wide
array
of
functions
affecting
cellular
activities
such
as
cell
cycle,
apoptosis,
DNA
damage
response,
and
hematopoiesis.
Due
to
the
multi-functionality
MYC,
its
expression
regulated
at
multiple
levels.
Deregulation
this
can
give
rise
variety
cancers.
In
review,
regulation
mechanisms
by
which
adjusts
implication
in
hematologic
malignancies
are
summarized.
Further,
we
also
discuss
potential
inhibitors
that
could
be
beneficial
for
treating
malignancies.
Cancer Research,
Journal Year:
2021,
Volume and Issue:
81(24), P. 6142 - 6156
Published: Oct. 26, 2021
Abstract
Cisplatin
(CDDP)-based
chemotherapy
is
the
first-line
treatment
for
muscle-invasive
and
metastatic
bladder
cancer,
yet
most
patients
rapidly
develop
resistance.
N6-methyladenosine
(m6A)
methylation
a
pervasive
RNA
modification,
its
specific
role
potential
mechanism
in
regulation
of
CDDP
chemosensitivity
cancer
remain
unclear.
Furthermore,
studies
have
not
fully
elucidated
whether
circular
(circRNA)
can
directly
regulate
m6A
modification
mRNA.
Here
we
report
upregulation
novel
circRNA,
hsa_circ_0008399
(circ0008399),
by
eukaryotic
translation
initiation
factor
4A3
(EIF4A3)
tissues
cell
lines.
Functionally,
circ0008399
inhibited
apoptosis
cells.
Mechanistically,
bound
Wilms'
tumor
1–associating
protein
(WTAP)
to
promote
formation
WTAP/METTL3/METTL14
methyltransferase
complex.
Circ0008399
increased
expression
TNF
alpha-induced
3
(TNFAIP3)
increasing
mRNA
stability
an
m6A-dependent
manner.
In
with
high
WTAP
was
associated
poor
outcomes.
Importantly,
activation
circ0008399/WTAP/TNFAIP3
pathway
decreased
CDDP,
targeting
axis
enhanced
efficacy.
Collectively,
these
findings
give
insights
into
circRNA-mediated
modifications
provide
therapeutic
targets
cancer.
Significance:
A
newly
characterized
circRNA
binds
modulate
target
through
reduce
cisplatin
sensitivity
implicating
value
this
axis.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2023,
Volume and Issue:
42(1)
Published: March 17, 2023
Abstract
Background
Small
cell
lung
cancer
(SCLC)
is
the
most
aggressive
subtype
of
cancer.
Although
patients
are
initially
sensitive
to
first-line
combination
chemotherapy
with
cisplatin
and
etoposide,
drug
resistance
easily
develops
quickly
leads
tumour
progression.
Therefore,
understanding
mechanisms
how
reverse
it
key
improving
prognosis
SCLC.
Moreover,
N6-methyladenosine
(m6A)
abundant
mRNA
modification
catalysed
by
methyltransferase
complex,
in
which
methyltransferase-like
3
(METTL3)
sole
catalytic
subunit.
Methods
The
effects
METTL3
on
chemoresistance
SCLC
cells
were
determined
using
qRT–PCR,
Western
blotting,
immunohistochemistry,
counting
kit
(CCK-8)
assays,
flow
cytometry,
tumorigenicity
experiments.
Methylated
RNA
immunoprecipitation
sequencing
(MeRIP-seq),
MeRIP
qPCR,
immunofluorescence,
inhibitor
experiments
performed
confirm
molecular
mechanism
Decapping
Protein
2
(DCP2),
involved
Results
In
present
study,
we
found
that
a
marker
for
poor
prognosis,
highly
expressed
chemoresistant
cells.
promotes
positively
regulating
mitophagy.
induces
m6A
methylation
DCP2
causes
degradation
DCP2,
mitochondrial
autophagy
through
Pink1-Parkin
pathway,
leading
resistance.
We
also
STM2457,
novel
inhibitor,
can
chemoresistance.
Conclusions
regulates
pathway-mediated
mitophagy
damage
targeting
thereby
promoting
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: April 28, 2022
Cancer
is
one
of
the
major
diseases
threatening
human
life
and
health
worldwide.
Epigenetic
modification
refers
to
heritable
changes
in
genetic
material
without
any
nucleic
acid
sequence
results
phenotypic
changes.
modifications
regulate
many
biological
processes,
such
as
growth,
aging,
various
diseases,
including
cancer.
With
advancement
next-generation
sequencing
technology,
role
RNA
cancer
progression
has
become
increasingly
prominent
a
hot
spot
scientific
research.
This
review
studied
several
common
modifications,
N6-methyladenosine,
5-methylcytosine,
pseudouridine.
The
deposition
roles
these
coding
noncoding
RNAs
are
summarized
detail.
Based
on
background,
this
expression,
function,
underlying
molecular
mechanism
their
regulators
further
discussed
some
existing
small-molecule
inhibitors.
More
in-depth
studies
needed
broaden
understanding
epigenetics
diagnosis,
treatment,
prognosis.
